Blog
No regulator has approved a GLP-1 microdose protocol. One randomized dose-ranging trial still tested those low doses. Here is what it found and what it did not.
Zepbound is tirzepatide, Wegovy is semaglutide. The head to head trial favored tirzepatide, but the two FDA labels now cover different conditions. Here is how to choose.
Sermorelin has never had an FDA-approved adult dose. The only labeled doses were pediatric and diagnostic. Here is what the research actually used and what it found.
ARA-290 has five published human trials, more than most peptides sold online. Nerve fiber density improved; pain did not separate from placebo. Here is what the research actually shows.
Melanotan II has never been approved by any regulator. Its efficacy evidence is one 1996 pilot study in three men; its safety record is roughly twenty case reports. What that
Selank is a synthetic seven-amino-acid peptide developed in Russia and studied as an anxiolytic. Here is what the published research shows and what remains unproven.
MK-677 (ibutamoren) is not a peptide but a small synthetic molecule that activates the ghrelin receptor. Here is what the clinical trials actually found and what that means for you.
An IV drip will not reset your body clock. Here is what a travel-recovery IV can restore after a long flight, and what actually helps your body clock adjust.
The FDA-approved tesamorelin dose depends on which formulation you have, and many online guides still quote a discontinued one. Here is what the current Egrifta WR label actually says.
EBOO is not dialysis and not plasma exchange. What each procedure removes, what the evidence shows, and why EBO2 has no literature at all.
What the published evidence actually shows about GHK-Cu dosing, and the 2026 FDA status by route.
EBOO therapy side effects, who should avoid it, and why insurance does not cover EBOO in the US.
